FDA drug, device postmarket programs to be audited by GAO at Rep. Wyden's request.
Executive Summary
FDA DRUG, DEVICE POSTMARKET SURVEILLANCE PROGRAMS TO BE EXAMINED BY GAO at the request of Rep. Wyden (D-Ore.). General Accounting Office staffers say an initial meeting on the audit with personnel from the agency's device and drug centers is scheduled for the week of May 1. In an April 12 letter, Wyden asks GAO "to assess the scope and adequacy" of FDA's device and drug post-market surveillance programs. The study also is to include "an examination of the extent to which FDA is able to monitor other countries' experience with newly approved pharmaceuticals, and translate that information into findings and appropriate actions protecting U.S. consumers."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth